Recent studies have indicated an important role of chemokines such as CCL2 in the development of chronic pain. However, the distinct roles of different chemokines in the development and maintenance of neuropathic pain and in their interactions with neurons have not been clearly elucidated. We found that spinal nerve ligation (SNL) not only induced persistent neuropathic pain symptoms, including mechanical allodynia and heat hyperalgesia, but also produced sustained CXCL1 upregulation in the spinal cord. Double staining of immunofluorescence and in situ hybridization revealed that CXCL1 was primarily induced in spinal astrocytes. In cultured astrocytes, tumor necrosis factor-a induced robust CXCL1 expression via the activation of the c-jun N-terminal kinase. Intrathecal administration of CXCL1 neutralizing antibody transiently reduced SNL-induced pain hypersensitivity, suggesting an essential role of CXCL1 in neuropathic pain sensitization. In particular, intraspinal delivery of CXCL1 shRNA lentiviral vectors, either before or after SNL, persistently attenuated SNL-induced pain hypersensitivity. Spinal application of CXCL1 not only elicited pain hypersensitivity but also induced rapid neuronal activation, as indicated by the expression of phosphorylated extracellular signal-regulated kinase and cAMP response element binding protein, and c-Fos in spinal cord neurons. Interestingly, CXCR2, the primary receptor of CXCL1, was upregulated in dorsal horn neurons after SNL, and the CXCR2 antagonist SB225002 completely blocked the CXCL1-induced heat hyperalgesia. SB225002 also attenuated SNLinduced pain hypersensitivity. Collectively, our results have demonstrated a novel form of chemokinemediated glial-neuronal interaction in the spinal cord that can drive neuropathic pain. Inhibition of the CXCL1-CXCR2 signaling may offer a new therapy for neuropathic pain management. Ó
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Introduction
Neuroinflammation has been recently recognized for its pivotal role in the pathogenesis of neuropathic pain as well as in inflammatory pain [34, 74] . Nonneuronal cells such as glial cells (astrocytes and microglia) become reactive following peripheral nerve injuries and contribute to the enhancement and maintenance of neuropathic pain by releasing growth factors (eg, brain-derived neurotrophic factor and basic fibroblast growth factor) and inflammatory mediators (eg, proinflammatory cytokines and chemokines) [1,2,18,26,49,58]. Chemokines are a family of functionally related small secreted molecules with established roles in the modulation of numerous biological functions, including leukocyte migration and activation, cell adhesion, and T-cell activation, and have been demonstrated to regulate neuroinflammation at different anatomical locations, including nerve, dorsal root ganglion (DRG), spinal cord, and brain [46, 47, 63, 74] . Increasing evidence has implicated chemokines in chronic pain processing following nerve injury [2, 18] .
CXCL1 belongs to the CXC family and is also known as keratinocyte-derived chemokines (KC), growth-related oncogene (GRO), or cytokine-induced neutrophil chemoattractant-1 (CINC-1). CXCL1 in rodents plays similar biological roles as interleukin-8 (IL-8) in humans [70] . In the peripheral tissue, CXCL1 is involved in neutrophil chemotaxis and degranulation at early phase of inflammation. Recent studies have shown that spinal nerve ligation and localized inflammation of DRG induced rapid upregulation of CXCL1 in the DRG [40, 75] . CXCL1 modulates neuronal excitability of DRG neurons by increasing sodium currents, potassium currents, and the function of transient receptor potential V1 channels [14, 71, 77] . It also stimulates calcium influx and calcitonin gene-related peptide
